PURPOSE OF REVIEW: Intrahepatic cholangiocarcinoma (ICC) is a treatment-refractory disease with a dismal outcome. Limited success in the clinical management and a persistent increase in the incidence world-wide have made ICC one of the most lethal and fastest growing malignancies. However, recent advancements in genome-wide technologies combined with the application of integrative multidimensional analytical approaches have begun to provide both detailed insight into the underlying biological traits of ICC and identified new therapeutic opportunities. RECENT FINDINGS: In comparison with other cancers, genomic studies of ICC have been limited. We and others have recently procured large cohorts of ICC patients intended for genome-wide analyses. In our study, samples from ICC patients were obtained from three cancer centers and subjected to integrated genetic and genomic analyses. We provided new insights into both pathogenesis and optimal treatment options demonstrating the presence of unique subclasses of patients, based partly on KRAS mutations and increased levels of receptor tyrosine kinase signaling. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes regulating inflammation and proteasome activities, suggesting a combination of tyrosine kinase inhibitors and anti-inflammatory drugs as a new therapeutic option for these patients. SUMMARY: We have critically examined the progress in genome-wide studies of ICC including genetic profiling, transcriptomics, and epigenomics. Current limitations in applying these technologies to archival samples and the insufficient access to fresh-frozen material are partly the cause of the delayed implementation of the omics-based investigations of ICC compared to other hepatobiliary diseases. Thus, selected candidate single-gene studies will also be discussed.
PURPOSE OF REVIEW: Intrahepatic cholangiocarcinoma (ICC) is a treatment-refractory disease with a dismal outcome. Limited success in the clinical management and a persistent increase in the incidence world-wide have made ICC one of the most lethal and fastest growing malignancies. However, recent advancements in genome-wide technologies combined with the application of integrative multidimensional analytical approaches have begun to provide both detailed insight into the underlying biological traits of ICC and identified new therapeutic opportunities. RECENT FINDINGS: In comparison with other cancers, genomic studies of ICC have been limited. We and others have recently procured large cohorts of ICC patients intended for genome-wide analyses. In our study, samples from ICC patients were obtained from three cancer centers and subjected to integrated genetic and genomic analyses. We provided new insights into both pathogenesis and optimal treatment options demonstrating the presence of unique subclasses of patients, based partly on KRAS mutations and increased levels of receptor tyrosine kinase signaling. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes regulating inflammation and proteasome activities, suggesting a combination of tyrosine kinase inhibitors and anti-inflammatory drugs as a new therapeutic option for these patients. SUMMARY: We have critically examined the progress in genome-wide studies of ICC including genetic profiling, transcriptomics, and epigenomics. Current limitations in applying these technologies to archival samples and the insufficient access to fresh-frozen material are partly the cause of the delayed implementation of the omics-based investigations of ICC compared to other hepatobiliary diseases. Thus, selected candidate single-gene studies will also be discussed.
Authors: Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding Journal: HPB (Oxford) Date: 2011-03-10 Impact factor: 3.647
Authors: Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer Journal: Hepatology Date: 2009-05 Impact factor: 17.425
Authors: Andrea Tannapfel; Florian Sommerer; Markus Benicke; Lars Weinans; Alexander Katalinic; Felix Geissler; Dirk Uhlmann; Johann Hauss; Christian Wittekind Journal: J Pathol Date: 2002-08 Impact factor: 7.996
Authors: R Sriraksa; C Zeller; M A El-Bahrawy; W Dai; J Daduang; P Jearanaikoon; S Chau-In; R Brown; T Limpaiboon Journal: Br J Cancer Date: 2011-03-29 Impact factor: 7.640
Authors: George Miller; Nicholas D Socci; Deepti Dhall; Michael D'Angelica; Ronald P DeMatteo; Peter J Allen; Bhuvanesh Singh; Yuman Fong; Leslie H Blumgart; David S Klimstra; William R Jarnagin Journal: J Exp Clin Cancer Res Date: 2009-05-12
Authors: Jeffrey S Ross; Kai Wang; Laurie Gay; Rami Al-Rohil; Janne V Rand; David M Jones; Hwa J Lee; Christine E Sheehan; Geoff A Otto; Gary Palmer; Roman Yelensky; Doron Lipson; Deborah Morosini; Matthew Hawryluk; Daniel V T Catenacci; Vincent A Miller; Chaitanya Churi; Siraj Ali; Philip J Stephens Journal: Oncologist Date: 2014-02-21